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Abstract
Since its initial recognition in December 2019, Coronavirus disease 19 (COVID-19) has quickly spread to a pandemic
infectious disease. The causative agent has been recognized as a novel coronavirus, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), primarily affecting the respiratory tract. To date, no vaccines are available nor any
specific treatment. To limit the number of infections, strict directives have been issued by governments that have been
translated into equally rigorous guidelines notably for post-mortem examinations by international and national scien-
tific societies. The recommendations for biosafety control required during specimen collection and handling have
strongly limited the practice of autopsies of the COVID-19 patients to a few adequate laboratories. A full pathological
examination has always been considered an important tool to better understand the pathophysiology of diseases,
especially when the knowledge of an emerging disorder is limited and the impact on the healthcare system is
significant. The first evidence of diffuse alveolar damage in the context of an acute respiratory distress syndrome
has now been joined by the latest findings that report a more complex scenario in COVID-19, including a vascular
involvement and a wide spectrum of associated pathologies. Ancillary tools such as electron microscopy and molecular
biology used on autoptic tissue samples from autopsy are also significantly contributing to confirm and/or identify new
aspects useful for a deeper knowledge of the pathogenetic mechanisms. This article will review and summarize the
pathological findings described in COVID-19 until now, chiefly focusing on the respiratory tract, highlighting the
importance of autopsy towards a better knowledge of this disease.
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Introduction
The viral family Coronaviridae are enveloped, positive-sense,
single-stranded RNA viruses, and typically cause mild respi-
ratory diseases in humans [1]. Coronavirus disease 2019
(COVID-19) is caused by the newly emerging severe acute
respiratory syndrome (SARS)-related coronavirus species 2 or
SARS-CoV-2, which suddenly poses a major health burden to
humans. Together with SARS-CoV, the agent of SARS, and
MERS-CoV, which causes the middle-east respiratory syn-
drome (MERS), it represents the third most severe coronavi-
rus disease within the past two decades, currently affecting
nearly 8 million patients and with more than 500,000 deaths
all over the world. COVID-19 was first recognized in Wuhan,
China, in December 2019, wherein a cluster of severe pneu-
monias occurred in people visiting a seafood and wildlife
market [2, 3]. It is thought that this event specifies the origin
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of the current pandemic, wherein humans potentially acquired
the pathogen via animal contact, although newer epidemiolog-
ical data suggest that the virus might already have circulated
earlier. Certain bat species are the natural reservoir for
Coronaviridae, but genetic adaptation of the viruses in inter-
mediate hosts seems to play a key role for crossing species
barriers and the subsequent transmission to humans. The in-
termediate hosts for SARS were probably civet cats and rac-
coon dogs, whereas camels play this role in MERS. In
COVID-19, pangolins might have served as such vectors
and it is likely that from them, human infection occurred [4].
SARS-CoV-2 infects human cells via binding to the
angiotensin-converting enzyme 2 (ACE2) that is highly
expressed on epithelial cells of the respiratory tract (e.g., bron-
chial transient secretory cells), endothelial cells but also on
several other cell types [5]. The viral spike (S) glycoprotein,
which extrudes from the virion surface, enables attachment to
ACE2, and due to cleavage of the S protein by host cell pro-
teases (e.g., via TMPRSS2), fusion of viral and cellular mem-
branes is facilitated to enable viral host cell entry [6]. Thus, the
interference of SARS-Cov-2 with multiple physiological pro-
cesses in several types of cells explains the observed variety of
clinical manifestations. Moreover, secondary effects mediated
via inflammation and the immune response (e.g., the so-called
“cytokine storm”) also seem to contribute significantly to
COVID-19 [7]. Clinical manifestations as well show different
grades of severity. Risk factors for the development of more
severe forms are generally older age and the presence of co-
morbidities like coronary artery disease, chronic kidney dis-
ease, hypertension, obesity, and diabetes type II [8–10]. To
that end, there is an urgent need for a better definition of the
pathogenetic mechanisms and of the primary and secondary
pathologies prevalent in SARS-CoV-2 infection to improve
patient care, which could also account for the great variance
in the reported case-fatality rates. Such insights might directly
enable development of specific therapies to counteract
COVID-19.
Awareness about the complexity of this disease has grown
over time since its outbreak. Pathological examinations, main-
ly obtained from autopsy material, have strongly contributed
to increase our knowledge of this infection. As expected, the
respiratory tract represents the most important target of the
disease. Nevertheless, studies focusing on pulmonary pathol-
ogy are scarce, probably because of the low number of inva-
sive procedures that were performed especially during the first
period of the spread. Indeed, the sudden outbreak, the high
number of hospitalizations, the shortage of health care person-
nel, and the high rate of potential contagiousness have limited
such procedures. Furthermore, the recommendations for bio-
safety and infection control required during specimen collec-
tion and handling have further affected autopsy practices. To
the best of our knowledge, only three papers have focused on
histological evaluation of in vivo surgical specimens [11–13]
with the main reported pathological findings being diffuse
alveolar damage (DAD), organizing pneumonia (OP), reac-
tive type II pneumocytes, and chronic interstitial pneumonia.
A more complex scenario is that reported by autopsy studies.
This article attempts to provide a comprehensive review of all
histological lung lesions reported in the autoptic studies thus
far.
Pulmonary pathology
The importance of autopsy and biosafety guidelines
The performance of autopsies is widely recognized since
many decades as a crucial part of routine pathology prac-
tice. However, in the twentieth century, the rate of autop-
sies decreased significantly, due to factors like improved
diagnostic technologies increasing accurate ante-mortem
diagnosis, the more complex legislation regarding human
tissue examinations, and an insufficient priority given to
autopsies by pathologists themselves, struggling with in-
creasing workloads of surgical resections, biopsies, and
cytology [14]. Nevertheless, autopsy, followed by micro-
scopic examination of the tissue samplings, still plays a
critical role in the diagnosis and in the uncovering the
pathophysiology of a newly emerging, yet unknown dis-
eases. Although the declining autopsy rate has been a
source of concern to pathologists, clinicians, infectious dis-
ease specialists, microbiologists, and epidemiologists in-
creasingly recognize that autopsy is a valuable tool for
the evaluation and, ultimately, the control and prevention
of emerging and re-emerging infectious diseases [15]. The
opportunity of performing post-mortem examinations of
patients deceased due to COVID-19 has raised significant
concerns motivated by the potential risk of contagiousness.
Indeed, the first indications were restrictive and initially
discouraged autopsies [16–20]. Surely, the balance of safe-
ty and providing quality results is a delicate process that
requires strong administration support and leadership.
Indeed, both the Centers for Disease Control and
Prevention (CDC) and the World Health Organization re-
leased documents to provide interim guidelines for the col-
lection, handling, and analysis of clinical specimens that
might contain SARS-CoV-2 [21, 22], initially based on
previous recommendations for SARS-CoV or MERS-
CoV [23]. A crucial point was the risk assessment that
has to be conducted in each laboratory, as well as other
core processes and procedures that need to be in place to
support laboratory biosafety practices when handling a
specimen from a patient under investigation for COVID-
19 [23–25]. The CDC updated the interim guidelines in-
cluding specific considerations about the importance, col-
lection, and submission of post-mortem specimens from
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deceased persons with known or suspected COVID-19 and
included specific recommendations for biosafety and in-
fection control practices during autopsy procedures [26].
The College of American Pathologists supported the per-
formance of autopsies in the setting of emerging infectious
diseases such as COVID-19 and endorsed the recommenda-
tions in the CDC guidelines [27], allowing an increase in
number of autopsies performedworldwide and a better knowl-
edge on SARS-CoV-2-related pathology.
There are no guidelines regarding the sampling of whole
lungs from autopsy in the literature. Herein, we have reported
the lung sampling protocol performed at the University of
Padova (see “Autopsy/sampling protocol” section).
Pathology of lung lesions in COVID deceased patients
The number of published papers in academic journals
concerning this field of interest is still scarce. A search in
PubMed was done using the keywords “Autopsy and
COVID-19”, “Autopsy and SARS-CoV-2”, “Post-mortem
and COVID-19”, and the total number at our last review
(May 27, 2020) is 23 articles (Table 1, Fig. 1). In the table,
we have categorized pulmonary microscopic findings into
“alveolar damage”, “vascular injury”, and “airway damage”.
The first autoptic study published by a Chinese group in
February 2020 reported a post-mortem minimally invasive
core-needle-based tissue collection performed in a 50-year-
old man who died from COVID-19. The authors described
histological features greatly resembling those seen in SARS
and MERS coronavirus infections. Indeed, lung tissue sam-
ples showed DAD with cellular fibromyxoid exudates, des-
quamation of pneumocytes and hyaline membranes, and the
main pathological findings of early-phase acute respiratory
distress syndrome (ARDS). Moreover, edema, interstitial
mononuclear inflammatory infiltrates (mainly lymphocytic),
and multinucleated syncytial cells with viral cytopathic-like
changes were also present [28]. Other papers published in the
same period reported similar histological features [29–31],
and in two cases, vascular damage was also described as the
presence of microthrombi within pulmonary capillaries asso-
ciated to the features of acute lung injury [30, 31].
Interestingly, in April 2020, an increasing number of au-
topsies were performed, representing a crucial turning point in
the pathological view of the disease. Indeed, several studies
reported not only morphological aspects indicative of ARDS,
but overall other lesions, particularly a more consistent de-
scription of microvascular injury. Barnes et al. described se-
vere neutrophilic capillaritis in three COVID-19 autoptic pa-
tients. Small vessel injury with features of acute capillaritis
was found in association with neutrophilic infiltration into
the alveolar space and tracheal mucosa. Interestingly, the au-
thors reported a link between the aberrant neutrophilic extra-
cellular traps, so-called “NETs”, and the presence of organ
damage both in alveolar parenchyma and airways [32].
Magro et al. reported septal capillary injury accompanied by
extensive complement deposition of C4d and C5b-9 in two
patients. The authors described thrombogenic vasculopathy
also in the skin and notably a colocalization of COVID-19
spike glycoproteins with complement fractions, thus hypoth-
esizing virus-related complement pathway activation [33].
Acute lung lesions and microthrombi were also described in
the first report of complete autopsies in two patients who died
in Oklahoma (USA) [34]. The authors reported for the first
time the feasibility of molecular analysis on post-mortem
swabs and other superimposed or unrelated processes. The
first clear-cut evidence of viral-related endotheliitis in
COVID-19 autoptic samples was reported by Varga et al.
The authors demonstrated endotheliitis in different organs
(notable, the heart, kidney, lung, small bowel) and aggregates
of viral particles with dense circular surfaces and crucial
markers in injured endothelial cells. These findings suggested
that SARS-CoV-2 infection facilitated the induction of
endotheliitis, apoptosis, and pyroptosis in several organs as a
direct consequence of the host inflammatory response or, as
suggested by some authors, by the direct infection of the en-
dothelial cells [35]. The identification of viral particles in en-
dothelial cells represents a challenging task and a clear-cut
evidence is still lacking (see also “Electron microscopy” sec-
tion). Fibrin thrombi within small vessels and small pulmo-
nary arteries with endothelial damage along with acute lung
injury were also reported in the first asthmatic patient who
died of COVID-19 [36]. Vascular injury was also consistently
detected in six patients who died at different stages of the
disease, showing lymphocytic pneumonia and acute fibrinous
and organizing pneumonia (AFOP). Copin et al. questioned
whether DAD was a frequent injury and observed that there
was a more consistent presence of AFOP in severe forms [37].
A sudden death of a 58-year-old female diabetic patient who
had extensive lung lesions with diffuse proteinaceous edema,
hyaline membranes, prominent desquamating pneumocyte
hyperplasia with focal multinucleated cells and bizarre forms
was reported [38].
The two largest studies published by Swiss and German
groups included 21 and 12 COVID-19 patients, respectively
[39, 40]. In the first case series, the primary cause of death was
respiratory failure with exudative DAD, massive capillary
congestion often accompanied by microthrombi despite
anticoagulation and, interestingly, in half of the cases also a
superimposed bronchopneumonia [39]. This study provided
the first largest overview of post-mortem findings in 21
COVID-19 cases, reporting that hypertensive, elderly, obese,
male individuals with severe cardiovascular comorbidities as
well as those with blood group A may have a lower threshold
of tolerance for COVID-19 [39]. Almost in the same period,
Wichmann et al. reported deep venous thrombosis in a high
percentage of patients (58%). Venous thromboembolism was
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not suspected before death and pulmonary embolism was the
direct cause of death in four of them, thus suggesting an im-
portant role of COVID-19-induced coagulopathy in patient
mortality [40]. Pulmonary emboli occluding the main pulmo-
nary arteries were found to be fatal also in two patients de-
scribed by Grimes et al. who argued that the SARS-CoV-2
infection, like the influenza virus and SARS-CoV, could be
associated with coagulation disorders that may lead to throm-
bosis and disseminated intravascular coagulation [41].
Lax et al. evaluated gross and microscopic findings and
clinical correlations in 11 cases. Interestingly, even if ten pa-
tients received prophylactic anticoagulant therapy, thrombosis
of small and mid-sized pulmonary arteries was found to occur
to various extents along with DAD in all of them. The authors
suggested that a combination of both lesions (DAD and
thrombosis) could explain the rapid clinical deterioration in
severe COVID-19, and that more proactive expansion of cur-
rent anticoagulant strategies is desirable [42].
Adachi et al. reported the autopsy of an 84-year-old cruise
ship passenger who died from COVID-19 and lung pathology
showed exudative and organizing phases of DAD, similar to
that observed in the cases of severe acute respiratory syn-
drome. By evaluating copy numbers of SARS-CoV-2 by
real-time PCR in different specimens, the authors found that
the virus principally attacked the respiratory tract and was
significantly less present in other organs (brain, heart,
testicles, and kidney) and in specimens such as blood, urine,
feces, and rectal swab [43].
Yan et al. described an obese female patient of 44 years,
showing for the first time an extensive and widespread
perivascular lymphocytic cuffing with few foci of infiltration
within vessel walls but without fibrinoid necrosis, consistent
with non-necrotizing lymphocytic vasculitis. Notably, there
was no evidence of microthrombi but ultrastructural investi-
gation revealed fibrin aggregates within blood vessels, sug-
gesting an increased propensity toward clot formation [44].
Autoptic studies of three cases from Houston (USA) showed
DAD, diffuse microvascular involvement with intravascular
and extravascular fibrin deposition, and diffuse intravascular
trapping of neutrophils, hyaline membranes, thromboemboli,
and inflammatory, mainly lymphocytic, infiltration. The au-
thors found similar vascular lesions in other organs,
supporting the concept that pathogenesis of COVID-19 is re-
lated to direct viral injury in different organs with a conse-
quent procoagulant state with coagulopathy [45].
An important study has recently been published by
Ackermann et al. [46]. Histological examination of lungs
coming from seven deceased patients affected by COVID-19
was compared with that obtained from patients who died from
influenza A (H1N1) infection and uninfected control lungs.
While DAD with perivascular T cell infiltration was a com-
mon feature in SARS-CoV-2 and H1N1 infections, vascular
features were instead distinctive of COVID-19 and consistedT
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of severe endothelial injury, widespread thrombosis with mi-
croangiopathy, alveolar capillary microthrombi, and
neoangiogenesis [46]. Studies that are more recent confirm
the complexity of COVID-19, emphasizing the patchy distri-
bution of the disease, mainly focusing on acute lung injury
[47–49]. Similar lesions consisting in DAD and diffuse signs
of thrombosis and microangiopathy in the small vessels and
capillaries of the lungs have recently reported also in a small
series of African American community with COVID-19 [50].
Unfortunately, some information is not consistently report-
ed in these studies as, for example, small and large airways as
well as pleural tissue. Only nine studies have pointed out some
macroscopic and/or microscopic aspects, with pathological
ones being mainly related to bronchitis/bronchopneumonia
until now [see below for details].
Based on a careful revision of autoptic reports, we can
distinguish a timeline for the gathering of our knowledge
about histological findings: February–March and April–May
(Fig. 2). In February–March, four anecdotic case series were
published (seven patients in total), and the most described
pulmonary pathological lesions were those related to an
acute/subacute lung injury. In April–May, 19 articles focused
on a more consistent number of autoptic cases (99 patients in
total) and it was emphasized that COVID-19 lung lesions
included a complex disease involving several anatomic com-
partments in which the vascular bed was mainly affected.
Pulmonary and airway-associated lesions
Pulmonary-associated lesions are those unexpected findings that
pathologists reported after a careful macroscopic and histological
examination of autoptic lung tissue samples. Because autopsies
in known or suspected COVID-19 patients have not been per-
formed extensively, to date, limited information is available
about pulmonary lesions superimposed to COVID-19 pneumo-
nia. Lesions related to known chronic diseases and comorbidities
(such as emphysema, asthma, etc.) will not be considered.
The most frequent finding was superimposed broncho-
pneumonia (likely bacterial related), both focal and diffuse.
In the autoptic case described by Tian et al., there was evi-
dence of consolidation of abundant intra-alveolar neutrophilic
infiltration, consistent with bronchopneumonia of a
superimposed bacterial infection [29]. Even in the three most
numerous case series, bronchopneumonia was found in 33–
55% of cases [39, 40, 42]. Minimal submucosal inflammation
was described in the bronchi/bronchioles [48, 49], and in two
cases, tracheitis was also reported [39, 48]. Even if tracheitis
may be explained as an iatrogenic lesion in some patients
particularly in those who received invasive ventilation, the
finding that these lesions may also frequently occur in patients
without invasive ventilation (Padova experience, submitted
for publication) suggests that the trachea is an important target
of the disease. This, however, is not an unexpected finding
Fig. 1 a Padova protocol for lung
gross examination after sagittal
section of lungs: three specimens/
lobe (two peripheral and one
central) are sampled. When there
are other evident lesions or pleu-
ral effusions, additional sampling
is performed. Transversal section
of the trachea and small fragments
for cultural, molecular, and ultra-
structural analyses are collected. b
Video frame of the right lung
captured during the autopsy in a
COVID-19 patient (69-year-old
women). A marbled appearance
of the lung with bloody pleural
effusion was evident. c Cut sur-
face of the same lung after for-
malin fixation. The parenchyma
showed patchy areas of consoli-
dation and congestion
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considering that ACE-2 receptors are also expressed in the
upper respiratory tract. A recent study supports this hypothe-
sis, documenting important inflammationwith an intense scin-
tigraphy uptake on the proximal bronchi in a COVID-19 non-
smoker patient [51].
Another important pathological finding was aspiration
pneumonia with foreign material, squamous cells, and vege-
table matter within the airways [34]. In only one case, lung
cancer was reported as an unknown superimposed lesion and
it was histologically defined as large cell carcinoma [48]. In
our experience, other unexpected pulmonary lesions were also
found in COVID-19 autoptic cases, such as lung carcinomas
(small cell lung cancer and squamous cell carcinoma), neuro-
endocrine hyperplasia, aspergilloma, necrotizing granulomas,
and pleuro-parenchymal fibroelastosis (unpublished personal
data from Padova pathologist team). It may be surmised that
more extensive case series could lead to a better understanding
of the contributive role of other lesions in the progression and
outcome of the disease.
Comparison of the COVID-19 pandemic and with prior
coronavirus pandemics
Few papers have comparatively analyzed COVID-19 pandemic
with similar global coronavirus pandemics that occurred over
the last decades, such as SARS andMERS. Both diseases had a
high mortality and lethality rate. As for the more severe forms
of SARS-CoV-2 pneumonias, DAD was reported to be the
main histological finding described in the first autopsy case
for MERS in the world: the virus showed a tropism for epithe-
lium and was found in pneumocytes and syncytial cells while
no evidence of extra-pulmonary involvement was detected
[52]. SARS autopsy findings also revealed varying degrees of
acute lung injury. The histology varied with the stage of the
illness. DAD, bronchiolar fibrin, and airspace edema were
mainly detected when the duration of the disease was shorter
than 10 days. Organizing pneumonia, type II hyperplasia, squa-
mousmetaplasia, multinucleated giant cells, and acute broncho-
pneumonia were found in longer-lasting diseases [53].
Interestingly, a series of 20 SARS autopsies also showed the
involvement of the vascular bed. Indeed, vascular fibrin throm-
bi, pulmonary infarcts, and small and mid-sized pulmonary
endothelial damage were frequently described [54].
In summary, the most severe forms of SARS-CoV-2 cer-
tainly share some important similarities with prior coronavirus
pandemics. However, COVID-19 has more complex symp-
toms and progression. The large spectrum of clinical manifes-
tations and degrees of severity have only now been partially
explained. Further studies may reveal new insights into the
mechanisms of COVID-19.
Fig. 2 Timeline of autopsy studies focusing on lung lesions in COVID-
19 patients. Since the end of March, the increased number of full autop-
sies has led to a better knowledge of the pathophysiology of the disease.
Together with the features of acute lung injury, vascular involvement has
been reported. a, bAcute lung injury: hyalinemembrane in alveolar space
(hematoxylin and eosin stain, original magnification a × 100; b × 200). c,
dVascular damage: twomicrothrombi in lung small vessels (hematoxylin
and eosin stain, original magnification × 200), capillary inflammation
(hematoxylin and eosin stain, original magnification × 200). e Airway
inflammation: tracheal section showing a polymorphous inflammatory
infiltrate of the submucosal layers (hematoxylin and eosin stain, original
magnification × 200)
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Ancillary tools and techniques
Cytology and several ancillary techniques are now considered
the routine diagnostic armamentarium in surgical pathology
and are particularly helpful in autopsies, especially in case of
novel emerging infectious diseases.
Ancillary tools: cytology
During the COVID-19 pandemic cytology, laboratories are
being impacted in several ways [55]. Different respiratory
specimens either of SARS-CoV-2 infected or non-infected
patients are submitted for cytopathological examination. A
cytopathologist may observe morphological features caused
by viral infection. Processing of respiratory specimens poten-
tially infected with SARS-CoV-2 requires implementation of
biosafety measures in cytology laboratories. The first report
on cytopathological features in bronchoalveolar lavage speci-
mens of COVID-19 patients revealed a high number of acti-
vated plasma cells admixed with T lymphocytes and scattered
B cells [56]. This is a surprising observation since no hyaline
material or desquamated pneumocytes were found which
would have been expected based on the main histopathologi-
cal changes reported in COVID-19 lungs. SARS-CoV-2 in-
fection does not cause any specific cytomorphological fea-
tures. In various respiratory specimens, like sputum or bron-
choalveolar lavage, we might observe cytomorphological fea-
tures of acute lung injury and repair: increased number of
macrophages, atypical type 2 pneumocytes, squamous meta-
plastic cells, and multinucleated cells. Viral etiology might be
suspected based on cytoplasmic and nuclear changes in mac-
rophages and epithelial cells. Presence of cell and nuclear
enlargement, epithelial desquamation, foamy cytoplasm, larg-
er paranuclear cytoplasmic vacuoles, nuclear clearing,
intranuclear inclusions, all of which might be related to viral
infection, may represent a potential diagnostic pitfall [55].
Indeed, routine laboratory processing pleural effusion, bron-
chial washings and aspirates, bronchoalveolar lavage, and
rinsed transbronchial needle aspiration specimens need centri-
fugation and/or cytocentrifugation which produces aerosol
and causes the most potentially infectious working exposure.
Strict biosafety measures should be implemented to prevent
accidental or unintentional exposure to infection [55, 57].
Several guidelines have been published to help health care
workers operate safely in cytology laboratories [21, 58].
Concerning autoptic reports, a post-mortem cytological inves-
tigation of SARS-CoV-2 infection was performed only in very
few cases. Barton et al. first reported viral positivity in post-
mortem nasopharyngeal and bilateral lung parenchymal
swabs [34]. Moreover, a forensic case of a sudden unexpected
death was related to COVID-19 after analyzing dacron-tipped
swabs of the right and left main bronchi [38]. More recently,
also other cases have been investigated in post-mortem
cytological samples, not only in swabs [43, 45, 47, 49] but
also in pleural effusions [47].
Pleural effusions were radiologically and/or grossly men-
tioned in different studies on autoptic cases [42, 43, 45, 47,
50]. In particular, when case series were reported, the preva-
lence of pleural effusions was either relatively small (9% and
33%) [42, 45] or was not specified [47, 50]. In our experience
(University of Padova), pleural effusion was detected in more
than half the patients (59% of cases). We collected it when it
was more than 200 cc. When a formalin-fixed cell pellet was
processed for cytoblock evaluation, several reactive mesothe-
lial cells in a mild inflammatory background were present
(Fig. 3).
The value of cytological examination in COVID-19 may
be limited. Given its scarce contribution to the diagnosis and
the difficulties in sample management, several limitations re-
main unsolved especially in relation to the real risk-benefit
ratio.
Ancillary techniques
Electron microscopy
Electron microscopy (EM) represents an important ancillary
technique and provides important insights in COVID-19 lung
tissue including autopsy material. Transmission EM (TEM)
could be particularly useful for identifying SARS-CoV-2 in
specific cells or subcellular compartments. Almeyda and
Tyrrell first described the characteristic ultrastructural mor-
phology of coronavirus particles in 1965 from organ cultures
of respiratory epithelium [59]. The virions were roundish,
ranging from 80 to 120 nm in diameter, and with 20-nm long
tail-like projection. Subsequent electron microscopy studies
carried out on fetal lung cell cultures have more fully investi-
gated the morphological characteristics of the virus [60]. The
spherical particles filled the cisternae of the endoplasmic re-
ticulum of infected cells mostly in perinuclear areas and were
present in the extracellular spaces following the cell lysis.
SARS-CoV-2 shares the morphological features of the
Coronaviridae family [61]. The first ultrastructural in vivo
study of SARS-CoV-2 in lung was performed on bronchoal-
veolar lavage fluid samples [62]. The authors demonstrated
the presence of cytoplasmic inclusion bodies containing the
typical virions only in the respiratory epithelial cells. Since
then, several autopsy studies have consistently used TEM to
assess the presence of SARS-CoV-2 particles in different tis-
sues and cell types. Experimentally, it has been observed that
the virus can infect engineered human blood vessel organoids
and human kidney organoids via the ACE-2 pathway [63].
This observation, together with the frequent findings of vas-
cular damage, has focused the research of the virus in vascular
tissues. Some authors reported the presence of putative SARS-
CoV-2 particles in the cytoplasm of endothelial cells [35, 40]
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but these observations have been questioned by experts [64].
TEM can be a powerful tool to find evidence of infection by a
virus, but care must be taken when interpreting unequivocally
such cytoplasmic structures as viral particles. There are nu-
merous structures found by TEM that resemble viruses (the so
called viral-like particles), such as endothelial tubuloreticular
inclusions, clathrin-coated vesicles at the trans-Golgi-net-
work, multivesicular bodies/autophagosomes or, straightfor-
wardly, cross-sections of the rough endoplasmic reticulum
(Fig. 4). The correct interpretation is even more difficult when
the ultrastructural study is carried out on autoptic samples
usually affected by several artifacts due to autolytic processes
or inadequate fixation. More advanced techniques, as the
immune-gold EM, are required to discern with certainty
whether these structures are SARS-CoV-2 virions. The study
of vascular alterations in COVID-19 has also been conducted
by scanning electron microscopy (SEM) analyses.
Ackermann et al. [46], using the microvascular corrosion cast-
ing method, highlighted the architectural distortion and the
loss of a clear vessel hierarchy of the alveolar vascular plexus
secondary to intussusceptive angiogenesis. The authors
showed a significantly greater density of intussusceptive an-
giogenic features in COVID-19 lungs as compared to influen-
za A and the control group. The results obtained from the
ultrastructural analyses of COVID-19 in the lungs are still
limited. A more extensive use of TEM, immunogold labeling,
or SEM may be appropriate to have a better understanding of
some altered subcellular structures.
Other tissue techniques
Outside the TEM approach, different tools have already been
used for many years to identify different coronavirus types in
human diseases such as those due to the MERS coronavirus
and the SARS-CoV, from formalin-fixed paraffin-embedded
(FFPE) tissue specimens, notably obtained from autopsies
[52, 65]. These tools include immunohistochemistry (IHC)
and in situ hybridization (ISH) as well as molecular biology
using real-time reverse transcriptase (RT) polymerase chain
reaction (PCR)-based assay from tissue sections and were thus
developed to identify the SARS-CoV-2 in FFPE tissue spec-
imens too. So far, during the COVID-19 pandemic, a few
studies have been published showing the usefulness of IHC
Fig. 3 Cyto-block preparation of pleural effusion fluid. Aggregates of
dysmorphic mesothelial cells with enlarged nuclei (a hematoxylin and
eosin, original magnification × 600) and multinucleated syncytial cell (b
hematoxylin and eosin, original magnification × 400). These features
suggest viral infection, as was confirmed by the positivity of RT-PCR
for SARS-CoV-2 on the cytological specimen
Fig. 4 Cytoplasm of type II pneumocyte from a post-mortem lung sample
of a COVID-19 patient. The molecular test RT-PCR for SARS-CoV-2
was positive on lung tissue. Post-mortem autolytic phenomena prevent a
precise visualization of sub-cellular compartments. There are several
spherical particles outlined with electron-dense dots that could mimic
coronavirus-like virions. Most probably, some of these particles are
clathrin-coated intracytoplasmic vesicles (arrowheads) or cross-sections
of the rough endoplasmic reticulum. Immunogold labeling would be
desirable to verify the nature of these putative viral particles. A
microvesicular body/autophagosome was also evident (arrow) (transmis-
sion electron microscopy, original magnification × 30,000)
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and ISH as well as RT-PCR to detect the SARS-CoV-2 from
FFPE tissue specimens, but rarely from samples taken during
autopsies [11, 31, 66, 67]. For a pathologist point of view,
IHC detection of SARS-CoV-2 virus in lung specimens is
the best way to combine etiology with morphological chang-
es. Liu et al. have recently used different antibodies to look for
the SARS-CoV-2 in infected FFPE cell pellets [66]. These
antibodies included a rabbit polyclonal anti-SARS-CoV-2
spike protein antibody and a mouse monoclonal anti-SARS-
CoV-2 nucleocapsid protein antibody. The authors also devel-
oped RNAscope ISH to identify SARS-CoV-2 RNA.
Additionally, they developed a dual staining assay using both
IHC and ISH to detect SARS-CoV-2 protein and RNA in the
same FFPE cell pellet sections [66]. This latter approach using
dual staining is certainly very interesting because a positive
IHC and RNA signal alone to detect the SARS-CoV-2 may
originate from degenerating RNA fragments or remaining free
viral antigens and not from viral particles. These approaches
need to be validated now in FFPE tissue sections from patients
infected by SARS-CoV-2, notably in samples taken during
autopsy. Using IHC with anti-Rp3 NP protein of SARS-
CoV-2, a study conducted by Zhang et al. using tissues col-
lected transthoracically with a minimally invasive core needle
revealed that the virus was present mainly in alveolar epithe-
lial cells [11]. Another study conducted by Yao et al. detected
SARS-CoV-2 nucleocapsid in post-mortem lung tissue in
both bronchiolar and type II alveolar epithelial cells using
monoclonal antibody against SARS-CoV-2 nucleocapsid. It
is noteworthy that this latter IHC was negative in different
post-mortem tissues including the heart, intestine, skin, liver,
and bone marrow [31]. The same antibody was used in other
studies [43] as well as for immunofluorescent microscopic
visualization of infected cells in bronchoalveolar lavage spec-
imens [3].
During the COVID-19 pandemic, SARS-CoV-2 has also
been identified by molecular biology using RT-PCR-based
assays in many human samples including bronchoalveolar
lavage, sputum, nasal swabs, bronchial brush biopsy, feces,
and blood [68]. It is noteworthy that RT-PCR can be used to
detect SARS-CoV-2 RNA in deparaffinized tissue sections
from different FFPE tissue samples as well [11]. RT-PCR
was also performed in autopsy samples [29, 40, 43]. One
problem with molecular analyses is the PCR performance
with the risk of false negative and/or false positive results in
suspected cases with typical COVID-19 clinical/radiological
characteristics [69–72]. There may also be problems in the
sampling, such as RNA degradation when storage systems
are inadequate. The protocol employed should be optimized
for FFPE tissue and the use of a kit designed for other pur-
poses should be avoided. Moreover, quantitative PCR assay
does not always allow for the discrimination between genomic
and subgenomic RNA, which contrasts with the important
need to assess viral replication.
The CDC and Prevention has designed a SARS-CoV2 RT
PCR diagnostic panel to minimize the chance of false positive
results (https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-
detection-instructions.html). This highlights the mandatory
necessity to be aware of using adequate positive and negative
controls in carrying out molecular tests for detecting SARS-
CoV2 from FFPE autopsy samples. In a very recent paper, RT-
PCR has been used with good results in FFPE specimens obtain-
ed from several major organs, giving important insights in the
pathophysiology of the disease [48]. The authors also performed
next-generation sequencing from post-mortem tissue samples
identifying a mutation that was quite consistent with a subset of
the Western European Clade A2a [48], overcoming the limits
reported by different papers about the use of such molecular
investigations in post-mortem tissue samples.
COVID-19 multiorgan involvement
Although the respiratory tract is the main target of COVID-19,
some clinical evidences suggest extra-pulmonary involvement.
Some case-series studies have emphasized that the renal, cardiac,
nervous, cutaneous, and gastrointestinal manifestations which oc-
cur during the disease may be related to SARS-CoV-2 infection
[73]. It remains unclear, however, if these manifestations are di-
rectly caused by infection of SARS-CoV-2, or to secondary phe-
nomena like inappropriate or overwhelming immune responses,
treatment effects or ischemia due to respiratory impairment or
thrombosis. A few authors have quantified viral load in several
types of tissues, finding lower levels of SARS-CoV-2 in the kid-
neys, liver, heart, and brain [74], thus supporting secondary rather
than primary involvement. This possibility might be justified by
the ubiquitous expression of ACE2 and would be in line with the
hypothesis of the multiorgan tropism of SARS-CoV-2.
Autopsy/sampling protocol
Postmortem examination of COVID-19 should be performed
in an autopsy suite, equipped if possible with a ventilation
system with six complete air changes/h (ACH) in a pressure-
negative environment, with air exhausted through HEPA fil-
ters [Biosafety Level 3 (BSL3)]. A detailed autopsy/sampling
protocol has recently been published by the University of
Padova Pathological Section [75]. The protocol requires that
a video registration be taken during the autopsy. The gross
examination and sampling of the whole lung is carried out in
the same manner as that used for explant lung evaluation.
After 72 h, the lungs can be weighed, sectioned, and sampled
in a total number of at least 16 samples (three samples per lobe
+ one at the hilum) for the lungs. Sampling is also carried out
when other lesions are present and are clearly visible during
the examination (Fig. 1).
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Conclusions
Using invasive diagnostic procedures to obtain tissue speci-
mens from COVID-19 patients is often not feasible consider-
ing the critical conditions of these patients with a high mor-
tality risk and the often-sudden clinical presentation.
Information coming from the most recent autopsy studies
has been crucial and has marked an important step forward
to gain better knowledge of the pathological substrates of
COVID-19.
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